BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 25880207)

  • 1. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
    Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
    Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
    Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
    Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil.
    Inoue K; Ishida K; Tomita G
    Jpn J Ophthalmol; 2018 Jul; 62(4):508-516. PubMed ID: 29797109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of latanoprost and timolol maleate in black and white patients.
    Kitnarong N; Zhao Y; Netland PA; Kent AR
    Adv Ther; 2004; 21(4):203-13. PubMed ID: 15605615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials.
    Zabriskie N; Netland PA;
    Adv Ther; 2003; 20(2):92-100. PubMed ID: 12836809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension.
    Harasymowycz P; Hutnik CM; Nicolela M; Stewart WC
    Can J Ophthalmol; 2007 Feb; 42(1):75-81. PubMed ID: 17361245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.